Safety Study of X-82 in Patients With Advanced Solid Tumors

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of X-82 as a single agent.

Timeline

Start

2011-02

Primary completion

2014-01

Completion

2017-01

Publications

• Bendell JC, Patel MR, Moore KN, Chua CC, Arkenau HT, Dukart G, Harrow K, Liang C. Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors. Oncologist. 2019 Apr;24(4):455-e121. doi: 10.1634/theoncologist.2018-0740. Epub 2018 Nov 26.

Drugs

Indications